Five Prime Therapeutics Inc. | Key People and Executives
Lewis T. Williams
Executive Chairman
Aron M. Knickerbocker
President, Chief Executive Officer & Director
Garry A. Nicholson
Independent Director
Sheila Gujrathi
Independent Director
Mark D. McDade
Lead Independent Director
Bill R. Ringo
Independent Director
Peder K. Jensen
Independent Director
Franklin M. Berger
Independent Director
Lewis T. Williams
Executive Chairman
Aron M. Knickerbocker
President, Chief Executive Officer & Director
Linda M. Rubinstein
Chief Financial & Accounting Officer
Bryan Irving
Chief Scientific Officer & Executive VP
Helen Collins
Chief Medical Officer & Senior Vice President
Kevin P. Baker
Senior Vice President-Development Sciences
Heather Rowe
Director-Investor Relations & Communications
Jeff P. Coon
Senior Vice President-Human Resources
Francis Willard Sarena
Secretary & Chief Strategy Officer
Garry A. Nicholson
Independent Director
Sheila Gujrathi
Independent Director
Mark D. McDade
Lead Independent Director
Bill R. Ringo
Independent Director
Peder K. Jensen
Independent Director
Franklin M. Berger
Independent Director
| Address |
111 Oyster Point Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.fiveprime.com |
| Updated |
07/08/2019 |
| Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. |
